Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 106
- Registration Number
- NCT03626012
- Locations
- 🇬🇧
Research Site, London, United Kingdom
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 109
- Registration Number
- NCT03573505
- Locations
- 🇬🇧
Research Site, Leeds, West Yorkshire, United Kingdom
🇺🇸Reserach Site, Houston, Texas, United States
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 66
- Registration Number
- NCT03507686
- Locations
- 🇩🇪
Research Site, Tübingen, Germany
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
- Conditions
- Choroideremia
- Interventions
- Genetic: BIIB111
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 169
- Registration Number
- NCT03496012
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT03454126
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
🇬🇧Research Site, Leeds, United Kingdom
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Biological: Tysabri
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80327
- Registration Number
- NCT03399981
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT03385525
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 654
- Registration Number
- NCT03352557
- Locations
- 🇺🇸
The Research Center of Southern California, Carlsbad, California, United States
🇸🇪Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden
🇮🇹Ospedale San Raffaele, Milano, Italy
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: SC interferon beta-1aDrug: SC interferon beta-1bDrug: SC Peginterferon beta-1a
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 626
- Registration Number
- NCT03347370
- Locations
- 🇩🇪
Research Site, Göttingen, Germany
Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
- Conditions
- Small Fiber NeuropathyDiabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 265
- Registration Number
- NCT03339336
- Locations
- 🇫🇷
CHU Nice - Hôpital de l'Archet 1, Nice, France
🇨🇿Nemocnice Pardubickeho kraje a.s. Pardubicka nemocnice, Pardubice, Czechia
🇩🇪Diabetologische Schwerpunktpraxis Harburg, Hamburg, Germany